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Abstract. Radiotherapy (RT) may result in platelet activation 
and thrombosis development. To the best of our knowledge, 
the potential effect of volumetric-modulated arc therapy 
(VMAT), a novel radiotherapy technique, on platelet function 
and microRNA (miRNA/miR) expression has not been previ-
ously investigated. The present study aimed to determine the 
effect of VMAT on the alterations in platelet function param-
eters and miRNA expression levels. A total of 25 patients 
with prostate cancer and 25 healthy subjects were included 
in the present study. Blood samples were collected from the 
patient group on the day prior to RT (pre-RT), the day RT 
was completed (post-RT day 0), and 40 days following the 
end of therapy (post-RT day 40). Platelet count, mean platelet 
volume (MPV) value, platelet aggregation, plasma P-selectin, 
thrombospondin-1, platelet factor 4, plasma miR-223 and 
miR-126 expression levels were measured. A significant 
decrease in platelet count in the post-RT day 0 group was 
measured in comparison with the pre-RT and the post-RT day 
40 groups. Pre-RT MPV values were higher than those of the 
post‑RT day 0 and the post‑RT day 40 groups. No significant 
differences were observed in the levels of platelet activation 
markers or miR-223 and miR-126 expression levels between 
the RT groups. Although RT may result in a reduction in 
platelet and MPV counts, the results of the present study indi-
cate that platelet activation markers are not affected by VMAT. 
Therefore, it is possible that no platelet activation occurs during 
VMAT, owing to the conformal dose distributions, improved 
target volume coverage and the sparing of normal tissues from 
undesired radiation.
Introduction
Prostate cancer was a common global malignancy among men 
in 2012 (1,2). Ionizing radiation is used to treat various types 
of cancer (3), including localized prostate cancer (4). External 
beam radiotherapy (RT) has been demonstrated to be a cura-
tive method for localized prostate cancer (5) by the European 
Association of Urology guidelines (6).
In addition to killing cancerous cells, ionizing radiation 
damages healthy cells. The hematopoietic system is an impor-
tant system in radiosensitive patients who are affected by the 
acute-phase effects of radiation (7). Ionizing radiation results 
in vascular damage through exertion of a cytotoxic effect on 
the vascular endothelium (8,9). Furthermore, homeostatic 
responses are activated due to oxidative damage that develops 
in the endothelium, including the activation of platelets in 
irradiated tissues, which results in platelet aggregation (9). The 
probability of thrombosis differs based on the type of cancer, 
with this probability varying between 6.9 and 11.4% in pros-
tate cancer (10). Platelets are known to serve notable functions 
in the formation of thrombosis (11,12).
Since the mid-90s, developments in techniques used in 
RT have allowed researchers to increase control over the 
tumor while decreasing the side effects that result from the 
treatment. These developments have additionally benefitted 
radiation therapy used for prostate cancer (5). A previous 
study performed with three-dimensional conformal RT 
(3D-CRT) in prostate cancer revealed that toxicity may be 
decreased if the target and the RT volume are compatible (6). 
Intensity-modulated RT (IMRT), a technique used in 3D-CRT, 
is the most common method used to treat prostate cancer. This 
method provides a better distribution of conformal doses, thus 
increasing the targeted dose distribution and decreasing the 
toxicity effect on normal tissues (5). A recently developed 
technique named volumetric-modulated arc therapy (VMAT) 
delivers the radiation dose more efficiently with a dynamic 
modulated arc (5,13); however, there are a limited number of 
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studies focusing on the effect on platelet functions in acute and 
chronic phases of radiation therapy applied using the VMAT 
technique. Studies performed on the effects of RT on platelet 
functions usually focus on specific markers, including platelet 
count and mean platelet volume (MPV) (7,14-16). In addition 
to platelet aggregation (17), the levels of P-selectin (18,19), 
thrombospondin-1 (20) and platelet factor 4 (PF 4) (21) are less 
commonly used parameters as markers of platelet function.
Previous molecular studies have revealed an association 
between serum/plasma levels and platelet levels and a number 
of microRNAs (miRNA/miRs), which direct gene expression 
by targeting mRNA at the post-transcriptional level (22,23). 
As miRNA expression levels may be altered in various types 
of disease, these tissue‑specific molecules may be used as 
disease markers by measuring their levels in circulation (24). 
It has been suggested that a number of miRNAs may addition-
ally be used as platelet activation markers (25-27).
A number of miRNAs are associated with platelet func-
tion, miR-223 and miR-126, which is expressed in platelets, 
are among the most commonly studied molecules. One 
previous study revealed that miR-223 and miR-126 serve a 
critical function in regulating the expression of vascular cell 
adhesion protein 1 and P2Y12 receptors in platelets (25). It 
has been reported that the altered plasma levels of these 
two miRNAs in cardiovascular diseases is associated with 
platelet function (24,26,27). This change may be plausible in 
post-treatment serum/plasma levels as a result of miRNAs 
released from platelets due to the toxic effect of RT. However, 
to the best of our knowledge, no studies have investigated 
this type of change caused by treatment with RT, particularly 
VMAT, on patients with prostate or other types of cancer. In 
the light of the aforementioned information, the present study 
was conducted to analyze the effect of VMAT on platelet 
function in patients with prostate cancer using previously 
determined markers, and to evaluate the association of plasma 
levels of miR-223 and miR-126 with treatment.
Materials and methods
Case selection. A total of 25 male patients (mean age 66.57, 
range 55‑76 years) diagnosed with histologically confirmed 
adenocarcinoma of the prostate and treated with RT at 
the Istanbul University Oncology Institute, Department of 
Radiation Oncology (Istanbul, Turkey) between June 2013 and 
February 2014 were included in the study. A total of 25 healthy 
male volunteers of similar age (mean age 63.76, range 
52-76 years), who did not receive any medication, constituted 
the control group. Medical history, including hematological 
disorders that affect platelet count or platelet function, distant 
metastases or other malignant diseases, diabetes, hyperten-
sion, chronic inflammatory diseases, infectious diseases and 
autoimmune diseases, were designated as exclusion criteria 
for the patients with prostate cancer. A known history of 
chronic, inflammatory or malignant diseases and the use 
of antithrombotic drugs were the exclusion criteria for the 
healthy control subjects. Patients with prostate cancer received 
therapy with VMAT (Varian Trilogy Rapid Arc Radiotherapy 
Device; Varian Medical Systems, Inc., Palo Alto, CA, USA) 
with a daily dose of 180-200 cGy fractions, 5 days a week 
for 30-37 days. The doses of the planned target volumes 
for prostate and seminal vesicles were 66-74 and 50-54 Gy, 
respectively. The total postoperative dose administered to 
the prostatic fossa was 66 Gy. Whole pelvis irradiation was 
not given. All patients gave written informed consent, and 
the present study was approved by the Istanbul University 
Cerrahpasa Medical Faculty Ethics Committee (approval 
number: 28052/2012) and the present study was performed in 
accordance with The Declaration of Helsinki.
Sample collection. Venous blood was collected into tubes 
containing 3.8% sodium citrate and EDTA separately from 
each person the day prior to RT (pre-RT group), the day RT 
was completed (post-RT day 0 group) and 40 days following 
the end of RT (post-RT day 40 group) from patients with pros-
tate cancer. The same volume of blood was collected into the 
tubes from healthy control subjects.
Platelet count and MPV values. Platelet counts and MPV 
values were determined using Cell-DYN C1600 (Abbott 
Pharmacuetical Co., Ltd., Lake Bluff, IL, USA) blood count 
device using blood collected as aforementioned.
Platelet aggregation. Platelet aggregation was determined 
according to the method of Angiolillo et al (28) using a light 
transmittance aggregometer (Chrono-log 500; Chrono Log 
Corp., Havertown, PA, USA). Venous blood samples were 
collected in tubes containing 3.8% sodium citrate. Platelet-rich 
plasma (PRP) was obtained as a supernatant subsequent to 
centrifugation of citrated blood at 160 x g for 10 min at 22˚C. 
The remaining blood was centrifuged at 2,500 x g for 10 min 
at 22˚C to obtain platelet poor plasma (PPP). PPP and PRP 
were incubated for 3 min at 37˚C. Following incubation, 1 µM 
of adenosine diphosphate (Chrono Log Corp.) was added into 
PRP to induce the platelet aggregation. Platelet aggregation 
curves were recorded for 3 min (29). Results were expressed as 
the extent of maximal aggregation (% of maximal amplitude).
Platelet activation. Venous blood samples containing 3.8% 
sodium citrate were centrifuged for 15 min at 1,000 x g at 
4˚C, and the obtained plasma samples were stored at ‑80˚C 
until plasma thrombospondin-1, P-selectin and PF 4 were 
measured using an ELISA. Subsequent to the thawing of each 
plasma sample at 4˚C, the measurements of plasma thrombo-
spondin-1 (EIAab Science Co. Ltd., Wuhan, Hubei, China; 
cat. no. E0611 h), P-selectin (Wuhan EIAab Science Co. Ltd.; 
cat. no. E0115 h) and PF 4 (Wuhan EIAab Science Co. Ltd.; cat. 
no. E0172 h) were performed using commercial kits according 
to the manufacturer's protocol.
miRNA detection with reverse transcription‑quantitative 
polymerase chain reaction (RT‑qPCR). EDTA-plasma 
samples stored at ‑80˚C were thawed at 4˚C prior to use 
and miRNA was immediately isolated by using the Qiagen 
miRNeasy Serum/Plasma kit (Qiagen GmbH, Hilden, 
Germany) following manufacturer's protocol. cDNA synthesis 
was synthesized using ABM miRNA cDNA Synthesis kit 
with Poly(A) Polymerase Tailing (ABM Inc., Vancouver, 
Canada) according to manufacturer's protocol. Samples 
were stored at ‑80˚C until further use. The expression levels 
of miRNAs were determined using the Eco™ Real-Time 
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PCR system (Illumina, Inc., San Diego, CA, USA). The 
primers used were as follows: Homo sapiens (hsa)-miR-223 
forward, 5'-GTC CGC TGT CAG TTT GTC AAA TAC-3' and 
reverse, 5'-GTG CGT GTC GTG GAG TC-3'; hsa-miR-126 
forward, 5'-GTC CGC TCG TAC CGT GAG TAA TA-3' and 
reverse 5'-GTG CGT GTC GTG GAG TC-3'; U6-2 forward 
5'-GCC CCT GCG CAA GGA TGA C-3' and reverse, 5'-CCA 
GTG CAG GGT CCG AGG TA-3'. All miRNA primers were 
procured from ABM Inc. RT-qPCR was conducted by using 
the EvaGreen miRNA qPCR MasterMix (Applied Biological 
Materials, Inc., Richmond, BC, Canada). The reaction condi-
tions were as follows: 1 cycle for 10 min at 95˚C, 40 cycles 
for (10 sec at 95˚C, 15 sec at 60˚C and 5 sec at 72˚C). Melting 
curve analysis was performed with a sensitivity of 0.1˚C 
at temperatures between 55 and 90˚C. PCR analyses were 
performed by calculating the standard curve and the number 
of duplicates. The Eco study software v5.0 (Illumina, Inc.) 
was used to calculate quantification cycle (Cq) expression 
values (30) for all genes. The U6-2 small nuclear RNA was 
used as an internal control to detect hsa-miR-223/miR-U6-2 
and hsa-miR-126/miR-U6-2 ratios in the plasma.
Statistical analysis. Data are presented as mean ± the standard 
deviation (SD). Statistical analysis was performed using the 
Wilcoxon signed-rank and Mann-Whitney U-tests. Correlation 
analysis using Spearman's rank was used to study the asso-
ciation between markers. P<0.05 was considered to indicate 
a statistically significant difference. Variation coefficiency 
(% Cv) was used to calculate the scattering due to individual 
variations. All calculations were performed using GraphPad 
Prism version 5.00 for Windows (GraphPad Software, Inc., La 
Jolla, CA, USA). Cv values were calculated as: % Cv=(SD of 
measurement/measurement average) x100.
Results
Patient data. Demographic data of patient and control groups 
are presented in Table I. Platelet count, MPV value and platelet 
activation markers are presented in Table II as the mean ± SD.
Platelet count and MPV value. The platelet count of the 
post‑RT day 0 group was significantly reduced vs. the pre‑RT 
and the post-RT day 40 groups (208.90±37.45 vs. 228.80±43.39 
and 232.80±44.79; P=0.002 and P=0.001, respectively). There 
were no significant differences identified (P>0.05) between 
the platelet count of the post-RT day 40 group and the pre-RT 
group, and all RT groups compared with the control group. 
Platelet count values are presented as the mean ± SD in 
Table II.
The MPV values of the pre‑RT group were identified to 
be higher than the post-RT day 0 and post-RT day 40 groups 
(8.81±0.81 vs. 8.34±0.79 and 8.19±0.81; P<0.001 and P<0.001, 
respectively). No significant difference in MPV values 
was identified between the post‑RT day 0 and post‑RT day 
40 groups (P>0.05). Furthermore, there were no significant 
differences identified (P>0.05) in the control group compared 
with the post-RT day 0 and post-RT day 40 groups. However, 
a significant difference was identified between the pre‑RT and 
control groups (P<0.05). MPV values are presented as the 
mean ± SD in Table II.
Platelet activation markers. Platelet aggregation, plasma 
P-selectin, plasma thrombospondin-1 and plasma PF 4 were 
measured as platelet activation markers. There was no signifi-
cant difference (P>0.05) between RT and control groups and 
among RT groups when platelet aggregation, plasma levels 
of P-selectin, thrombospondin-1 and PF 4 were measured 
(Table II). However, high values of plasma thrombospondin-1 
and PF 4 were observed in the coefficient of variation calcula-
tions used to determine the scattering due to personal variations 
(Cv 51.6 to 63.4 and 41.8 to 54.5%, respectively; data not shown).
miR‑223 and miR‑126 expression. Plasma expression levels of 
miR-223 and miR-126 are given as Cq miR-223/Cq miR-U6-2 
and Cq miR-126/Cq miR-U6-2 ratios (Fig. 1A and B, respec-
tively). No significant difference (P>0.05) was identified 
between the plasma miR-223 expression levels of the RT-treated 
and control groups and amongst the RT groups. Similarly, the 
miR‑126 expression levels did not vary significantly (P>0.05) 
between any of the groups (Table III). Fig. 2A-D shows the indi-
vidual changes in Cq miR-223/Cq miR U6-2 and Cq miR-126/Cq 
miR-U6-2 ratios in RT-treated groups. Ct miR-223/Ct miR 
U6-2 and Ct miR-126/Ct miR U6-2 ratios in patient and control 
groups values are presented as the mean ± SD in Table III.
Correlation between miRNA expression levels and platelet 
function markers. A positive correlation was identified 
between Cq miR-223/Cq miR-U6-2 and Cq miR-126/Cq 
miR-U6-2 ratios in all RT-treated groups. Correlation between 
Cq miR-223/Cq miR-U6-2 and Cq miR-126/Cq miR-U6-2 
ratios in all RT-treated groups are presented in Fig. 3A-C.
Discussion
RT kills target cells by inducing DNA damage (31). However, 
RT may also harm the cells of healthy tissues and mitotically 
active bone marrow as collateral damage (14). Various studies 
have reported the existence of occlusions in the vascular 
system in the chronic phase of irradiation and aggregation of 
Table I. Demographic data of patient and control groups.
Variables Patients Control P-value
Age, years 66.57±6.65a 63.76±8.49a 0.386
Histology   
  Adenocarcinoma, n (%) 25 (100) NA 
Tumor stage   
   T2c, n (%)    4 (16%) NA 
   T3b, n (%)  12 (48%) NA 
   T3c, n (%)    9 (36%) NA 
Total radiation dose, cGy 6,600-7,400 NA 
Fractions, n 30-37 NA 
Family history   
   Yes, n (%)   3 (12%) NA 
   No, n (%) 22 (88%) NA 
aMean ± standard deviation; NA, not applicable.
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platelets in the vascular lumen during the 2 h following irradia-
tion (32-34). Platelet adhesion to vascular wall structures due 
to radiation results in radiation-associated thrombosis (32).
VMAT was developed as a novel form of arc therapy 
in 2007 to decrease the side effects of RT (35). There are a 
number of benefits of VMAT, including increased target speci-
ficity and improved healthy tissue avoidance, in addition to 
improving coverage of the target area by adjusting the gantry 
rotation and speed, better dose distribution and significantly 
reduced RT time (36).
Although previous studies have revealed that targeted dose 
distributions are better managed by VMAT (36,37), to the best 
of our knowledge there is no concrete data elucidating the 
effect of VMAT on platelet markers. Therefore, the present 
study aimed to measure the platelet parameters and activation 
markers prior to and following RT to determine the effects 
of radiation administered with VMAT on the platelet count, 
MPV value, platelet aggregation, levels of P-selectin, throm-
bospondin-1 and PF 4 markers. Furthermore, their association 
with miR-226 and miR-123 expression levels in patients with 
prostate cancer was also determined.
The results of the present study indicated the presence of a 
significant difference in platelet count and MPV value in pre‑ 
and post-RT with VMAT treatment groups of patients with 
prostate cancer. According to the results, the platelet count was 
decreased by 8.7% in the post-RT day 0 group in comparison 
with the pre-RT group and increased by 10% in the post-RT 
day 40 group compared with the post-RT day 0 group. Previous 
studies investigating conventional RT and IMRT techniques 
have reported a decrease in platelet count following treatment, 
thus corroborating the results of the present study (7,15,38,39). 
Furthermore, it has been demonstrated that sub-lethal radia-
tion doses may result in abnormal hemostasis characteristics 
and coagulation biomarker values observed up to 21 days 
post-irradiation (40). Therefore, the post-RT decrease in 
platelet counts observed in the present study may be due to 
the suppressive effect of radiation on the hematopoietic system 
in the acute phase. The increase in the platelet count in the 
post-RT day 40 group may be associated with the removal of 
the suppressive effect of RT on bone marrow.
MPV is a marker of platelet function and activation. An 
increase in platelet volume may result in increased platelet 
activity. The changes in platelet volume may be used as a 































































































































































































































































































































































































































Table III. Cq miR-223/Cq miR U6-2 ratios in patient and 
control groups.
Patients Cq miR-223/ Cq miR-126/
(n=25 per group) Cq miR U6-2 Cq miR U6-2
Pre-RT 1.17±0.40 1.15±0.44
Post-RT day 0  1.31±0.41 1.22±0.38
Post-RT day 40  1.23±0.38 1.17±0.36
Control 1.19±0.23 1.21±0.20
Values are presented as the mean ± the standard deviation. RT, 
radiotherapy; miR, microRNA; Cq, quantification cycle.
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platelet-associated diseases (41). The formation and develop-
ment of thrombi largely depends on platelet activation, in 
which a change in platelet parameters may affect the activa-
tion process (42). The MPV is the average measurement of 
platelet size, and as the platelet increases in size, the potential 
of thrombus formation increases (41).
The present study revealed that MPV values were increased 
by 10% in the pre-RT group in comparison with the control 
group and decreased by 6% in the pre-RT day 0 group and 
10% in the pre-RT day 40 group comapred with the pre-RT 
group. These results indicated that MPV values were increased 
owing to cancer and decreased owing to RT. The MPV values 
were investigated in various types of cancer, including prostate 
cancer (43,44); however, to the best of our knowledge, there are 
no studies investigating the change in MPV values associated 
with RT.
The platelet function markers investigated in the present 
study include platelet aggregation, a marker of platelet hyper-
activity (45); P-selectin, an adhesion molecule, which is present 
in the alpha granules of platelets and released as a response to 
Figure 1. Ratio of miRNAs associated with platelet function in patients and controls. (A) Cq miR-223/Cq miR U6-2 ratios in patients prior to and following RT 
and control groups. (B) Cq miR-126/Cq miR U6-2 ratios in patients prior to and following RT and control groups. RT, radiotherapy; miR/miRNA, microRNA; 
Cq, quantification cycle.
Figure 2. Individual changes to the Cq miR-223/Cq miR U6-2 and Cq miR-126/Cq miR-U6-2 ratios in RT-treated groups. (A and B) Individual changes to Cq 
miR-223/Cq miR U6-2 ratios in RT-treated groups. (C and D) Individual changes to Cq miR-126/Cq miR U6-2 ratios in RT-treated groups. RT, radiotherapy; 
miR, microRNA; Cq, quantification cycle.
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cellular activities (46); thrombospondin-1, which is released 
during hemostatic plaque formation and an active player in 
thrombus formation (47), and PF 4, which serves a function 
in thrombosis and is released by platelet activation (48). When 
the data was evaluated, no significant change was identi-
fied in the levels of platelet aggregation, plasma P‑selectin, 
thrombospondin-1 and PF 4 associated with RT between any 
of the RT groups.
Various studies reported a notable but unsignificant 
increase in platelet aggregation levels in vitro and in patients 
with metastatic prostate cancer compared with pre-RT 
conditions (17,49). It has been suggested that extracorporeal 
irradiation does not affect the platelet functions that are 
already in systemic circulation, however, it may affect bone 
marrow platelet stem cells (17).
Experimental molecular studies that determine the 
effects of ionizing radiation on P-selectin levels revealed an 
increase in the concentration of P-selectin in association with 
RT (18,33,50). However, Zekanowska et al (19) reported that 
the levels of soluble P-selectin do not change following RT 
in patients with prostate cancer. The results of the present 
study revealed that RT did not affect the plasma P-selectin 
concentration in patients with prostate cancer.
It has been revealed that the concentration of throm-
bospondin-1 changes owing to an increasing dose of 
radiation over time (51,52). Lewinski et al (20) reported that 
thrombospondin-1 concentration did not change in asso-
ciation with the radioactive iodine treatment in patients with 
thyrotoxicosis.
Although contradictory results exist in clinical studies 
investigating PF 4 levels in various types of cancer (53-55), 
to the best of our knowledge no clinical studies have focused 
on the changes in plasma PF 4 levels associated with RT. 
A number of in vitro studies have provided evidence of the 
protective effect of PF 4 against the damaging effect of 
radiation (56,57).
At present, the basis for the lack of effect of VMAT on 
platelet function remains unknown, although VMAT has a 
partial effect on the platelet count and MPV value. A potential 
explanation for this is that the highly developed dose distribu-
tion of VMAT may result in platelet activation in the target 
area below detectable levels in systemic circulation.
miRNAs are small molecules that target specific genes and 
regulate their transcription (57). In previous years, it has been 
revealed that miRNAs serve functions in various pathological 
and physiological processes (57).
A previous study has reported alterations in miRNA expression 
in different diseases, and that platelet miRNA levels were biologi-
cally and clinically important markers of the following: i) Platelet 
protein translation and expression; ii) mature megakaryocyte 
Figure 3. Correlation between Cq miR-223/Cq miR-U6-2 and Cq miR-126/Cq miR-U6-2 ratios in RT-treated groups. Correlation between Cq miR-223/Cq miR 
U6-2 and Cq miR-126/Cq miR U6-2 ratios in (A) the pre-RT group, (B) the post-RT day 0 group and (C) the post-RT day 40 group. RT, radiotherapy; miR, 
microRNA; Cq, quantification cycle.
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miRNA level; iii) hematological disease and platelet reactivity; 
and iv) basic mechanisms of megakaryocyte/platelets (58). 
Although the exact function of miRNAs in platelet function is 
not clearly understood, it is thought that miRNAs have notable 
functions in hemostasis and thrombosis (57).
Studies published in previous years provide evidence that 
a number of miRNAs are specific to cells and tissues and are 
differentially expressed (24,59,60). It has been demonstrated 
that miRNAs can enter into systemic circulation via certain 
mechanisms, including exosome secretion, cell death and 
blebbing, and that these circulating miRNAs could be used 
as potential markers for and in the follow-up of certain 
diseases (24). So far, studies have focused on the changes 
of miRNA expression levels associated with cancer (1,61). 
However, to the best of our knowledge there are no studies that 
have investigated the effects of radiation on platelet miRNA 
expression. In experimental and total body irradiation studies, 
it has been reported that the expression rates of a number of 
miRNAs, including miR-126 and miR-223, change in plasma 
and peripheral blood cells. miR-223 and miR-126 are miRNAs 
identified in platelets. It has been revealed that miR‑223 targets 
the P2Y12 receptor that is present on platelets and inhibits 
it, thus suppressing platelet aggregation and activation (58). 
miR-126 is downregulated during megakaryocytopoiesis, 
indicating that it serves a function in differentiation (62).
Various studies have reported that changes in the plasma 
levels of miR-223 and miR-126 are associated with platelet 
function in cardiovascular diseases (24,26,27). Considering 
the effect of radiation on platelet functions from these previous 
studies, a change in the expression levels of miRNAs may be 
expected to exert an effect on platelet activation-associated 
RT. In vitro and experimental studies revealed that the 
expression levels of miR-223 and miR-126 changed over time 
with increasing radiation dose (63,64). Following RT, changes 
to RT-associated serum/plasma level changes can be expected 
as platelets release miRNAs as RT damages the cells. These 
changes may depend on the type and duration of treatment 
and the dose distribution. Thus, the present study additionally 
investigated the expression levels of miR-223 and miR-126 in 
the plasma and the changes in the expression of these miRNAs 
following VMAT application.
The results of the present study did not reveal a signifi-
cant change in miR-223 and miR-126 expression levels in 
association with VMAT in patients with prostate cancer. The 
lack of significant differences in miRNA expression between 
pre-RT and control groups may indicate that these miRNAs 
are not tumor‑specific in serum/plasma. The VMAT tech-
nique achieved highly conformal treatment plans and 
decreased the normal tissue toxicity compared with other 
conventional RT techniques (65). Therefore, no significant 
changes in the miRNA expression levels were observed. 
Dynamic changes to miRNA expression levels in response to 
antitumor therapy may have resulted in this non‑significant 
difference (66). However, in the present study, there existed 
a clear inter-individual variability to radiation response in 
terms of the expression of miRNAs. Notably, this situa-
tion may not be easily explained by previous observations. 
The cells of patients with cancer respond differently to RT, 
even when they are treated with the same curative dose. 
Furthermore, numerous different factors, including genetic 
variations, environmental stress, differences in nutritional 
state between patients and controls, and exposure to geno-
toxic chemical agents may affect individual responses to 
ionizing radiation (67-70). Therefore, further studies are 
required to understand the molecular events underlying the 
substantial inter-individual differences in miRNA expression 
in response to radiation.
There are a number of limitations to the present study, 
including its relatively small sample size, investigation of a 
limited number of miRNAs rather than all miRNAs associ-
ated with platelet activation and the focus on plasma samples. 
However, the levels of miRNA and activation markers in 
platelets may provide valuable data to evaluate the platelet 
function.
In summary, the present study demonstrated that there 
were no significant changes in platelet aggregation, plasma 
P-selectin, thrombospondin-1 and PF 4 levels and miR-226 and 
miR-123 expression in plasma associated with RT. However, 
a significant change in platelet count and MPV values were 
identified to be associated with RT. The results of the present 
study indicated that VMAT may not be a risk factor for platelet 
activation in patients with prostate cancer, despite the fact that 
it reduced the platelet count and MPV values, which may also 
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